Proteomic profile of differentially expressed plasma proteins from dystrophic mice and following suberoylanilide hydroxamic acid treatment

Proteomics - Clinical Applications

Volumn 4, Issue 1, 2010, Pages 71-83

  Colussi, C ^a   Banfi, C ^a   Brioschi, M ^a   Tremoli, E ^a   Straino, S ^c   Spallotta, F ^c   Mai, Antonello ^b   Rotili, Dante ^b   Capogrossi, M C ^c   Gaetano, Carlo ^c  

^a CENTRO CARDIOLOGICO MONZINO   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

Author keywords

Duchenne muscular dystrophy; Histone deacetylase inhibitors; Plasma proteome

Indexed keywords

ALPHA 2 MACROGLOBULIN; ALPHA ACTIN; APOLIPOPROTEIN E; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBRINOGEN; GELSOLIN; GLUTATHIONE PEROXIDASE 3; HISTONE DEACETYLASE INHIBITOR; LEUKEMIA INHIBITORY FACTOR RECEPTOR; PLASMA PROTEIN; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE MARKER; DISEASE MODEL; DOWN REGULATION; DRUG DOSE COMPARISON; DUCHENNE MUSCULAR DYSTROPHY; MASS SPECTROMETRY; MOUSE; MUSCLE REGENERATION; MUSCLE STRENGTH; NONHUMAN; NUCLEOTIDE SEQUENCE; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; TREATMENT OUTCOME; TWO DIMENSIONAL ELECTROPHORESIS; UPREGULATION; WESTERN BLOTTING; WILD TYPE; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

AMINO ACID SEQUENCE; ANIMALS; BLOOD PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; HYDROXAMIC ACIDS; MICE; MOLECULAR SEQUENCE DATA; MUSCULAR DYSTROPHY, DUCHENNE; PROTEOME; PROTEOMICS; REPRODUCIBILITY OF RESULTS;

ANIMALIA; MUS;

EID: 77951727320     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.200900116     Document Type: Article

References (32)

1. Muntoni, F., Torelli, S., Ferlini, A., Dystrophin and mutations: One gene, several proteins, multiple phenotypes. Lancet Neurol. 2003, 2, 731-740.
2. Doran, P., Donoghue, P., O'Connell, K., Gannon, J., Ohlendieck, K., Proteomic profiling of pathological and aged skeletal muscle fibres by peptide mass fingerprinting (Review). Int. J. Mol. Med. 2007, 19, 547-564.
3. Ge, Y., Molloy, M.P., Chamberlain, J.S., Andrews, P.C., Proteomic analysis of mdx skeletal muscle: Great reduction of adenylate kinase 1 expression and enzymatic activity. Proteomics 2003, 3, 1895-1903.
4. Gulston, M.K., Rubtsov, D.V., Atherton, H.J., Clarke, K. et al., A combined metabolomic and proteomic investigation of the effects of a failure to express dystrophin in the mouse heart. J. Proteome Res. 2008, 7, 2069-2077.
5. Omenn, G.S., Strategies for plasma proteomic profiling of cancers. Proteomics 2006, 6, 5662-5673.
6. Richon, V.M., Zhou, X., Rifkind, R.A., Marks, P.A., Histone deacetylase inhibitors: Development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers. Blood Cells Mol. Dis. 2001, 27, 260-264.
7. Minetti, G.C., Colussi, C., Adami, R., Serra, C. et al., Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors. Nat. Med. 2006, 12, 1147-1150.
8. Nakatani, M., Takehara, Y., Sugino, H., Matsumoto, M. et al., Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology inmdxmice. FASEB J. 2008, 22, 477-487.
9. A. Mai, M.E., Sbardella, G., Massa, S., A new facile and expeditious synthesis of N-hydroxy-N′-phenyloctanediamide, a potent inducer of terminal cytodifferentiation. Org. Prep. Proced. Int. 2001, 201, 391-394.
10. Saito, T., Yamamoto, Y., Matsumura, T., Nozaki, S. et al., Coagulation system activated in Duchenne muscular dystrophy patients with cardiac dysfunction. Brain Dev. 2005, 27, 415-418.
11. Chu, C.T., Howard, G.C., Misra, U.K., Pizzo, S.V., Alpha 2-macroglobulin: A sensor for proteolysis. Ann. N.Y. Acad. Sci. 1994, 737, 291-307.
12. Borth, W., Luger, T.A., Identification of alpha 2-macroglobulin as a cytokine binding plasma protein. Binding of interleukin-1 beta to "F" alpha 2-macroglobulin. J. Biol. Chem. 1989, 264, 5818-5825.
13. Bani, C., Lagrota-Candido, J., Pinheiro, D.F., Leite, P.E. et al., Pattern of metalloprotease activity and myofiber regeneration in skeletal muscles of mdx mice. Muscle Nerve 2008, 37, 583-592.
14. Souder, C., Leitzel, K., Ali, S.M., Demers, L. et al., Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer. Cancer 2006, 107, 2337-2345.
15. Gregorc, V., Ceresoli, G.L., Floriani, I., Spreafico, A. et al., Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer. Clin. Cancer. Res. 2004, 10, 6006-6012.
16. Bijian, K., Mlynarek, A.M., Balys, R.L., Jie, S. et al., Serum proteomic approach for the identification of serum biomarkers contributed by oral squamous cell carcinoma and host tissue microenvironment. J. Proteome Res. 2009, 8, 2173-2185.
17. Kucherenko, M.M., Pantoja, M., Yatsenko, A.S., Shcherbata, H.R. et al., Genetic modifier screens reveal new components that interact with the Drosophila dystroglycandystrophin complex. PLoS One 2008, 3, e2418.
18. Lee, W.M., Galbraith, R.M., The extracellular actinscavenger system and actin toxicity. N. Engl. J. Med. 1992, 326, 1335-1341.
19. Zhou, Y., Jiang, L., Rui, L., Identification of MUP1 as a regulator for glucose and lipid metabolism in mice. J. Biol. Chem. 2009, 284, 11152-11159.
20. Griffin, J.L., Des Rosiers, C., Applications of metabolomics and proteomics to the mdx mouse model of Duchenne muscular dystrophy: Lessons from downstream of the transcriptome. Genome Med. 2009, 1, 32.
21. Barnard, W., Bower, J., Brown, M.A., Murphy, M., Austin, L., Leukemia inhibitory factor (LIF) infusion stimulates skeletal muscle regeneration after injury: Injured muscle expresses lif mRNA. J. Neurol. Sci. 1994, 123, 108-113.
22. Austin, L., Bower, J.J., Bennett, T.M., Lynch, G.S. et al., Leukemia inhibitory factor ameliorates muscle fiber degeneration in the mdxmouse. Muscle Nerve 2000, 23, 1700-1705.
23. Dudley, R.W., Khairallah, M., Mohammed, S., Lands, L. et al., Dynamic responses of the glutathione system to acute oxidative stress in dystrophic mouse (mdx) muscles. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2006, 291, R704-710.
24. Whitehead, N.P., Yeung, E.W., Allen, D.G., Muscle damage in mdx (dystrophic) mice: Role of calcium and reactive oxygen species. Clin. Exp. Pharmacol. Physiol. 2006, 33, 657-662.
25. Mahley, R.W., Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology. Science 1988, 240, 622-630.
26. Vedhachalam, C., Narayanaswami, V., Neto, N., Forte, T.M. et al., The C-terminal lipid-binding domain of apolipoprotein E is a highly efficient mediator of ABCA1-dependent cholesterol efflux that promotes the assembly of high-density lipoproteins. Biochemistry 2007, 46, 2583-2593.
27. Krimbou, L., Tremblay, M., Jacques, H., Davignon, J., Cohn, J.S., In vitro factors affecting the concentration of gamma-LpE (gamma-LpE) in human plasma. J. Lipid Res. 1998, 39, 861-872.
28. Gailly, P., De Backer, F., Van Schoor, M., Gillis, J.M., In situ measurements of calpain activity in isolated muscle fibres from normal and dystrophin-lacking mdx mice. J. Physiol. 2007, 582, 1261-1275.
29. Colussi, C., Mozzetta, C., Gurtner, A., Illi, B. et al., HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 19183-19187.
30. Colussi, C., Gurtner, A., Rosati, J., Illi, B. et al., Nitric oxide deficiency determines global chromatin changes in Duchenne muscular dystrophy. FASEB J. 2009, 23, 2131-2141.
31. Safronova, O., Pluemsampant, S., Nakahama, K.I., Morita, I., Regulation of chemokine gene expression by hypoxia via cooperative activation of NF-kappaB and histone deacetylase. Int. J. Biochem. Cell Biol. 2009, 41, 2270-2280.
32. Choudhary, C., Kumar, C., Gnad, F., Nielsen, M.L. et al., Lysine acetylation targets protein complexes and coregulates major cellular functions. Science 2009, 325, 834-840.